Tesamorelin and sermorelin are both GHRH analogs that stimulate the body's own growth hormone, and both have regulatory histories — but different current standing. Tesamorelin is an actively FDA-approved drug (Egrifta) for HIV-related visceral fat; sermorelin was previously approved (Geref) and is now typically supplied through compounding.
At a glance
| Tesamorelin | Sermorelin | |
|---|---|---|
| Class | GHRH analog | GHRH analog (GHRH 1–29) |
| Brand name | Egrifta | Geref (discontinued) |
| FDA status | Approved | Formerly approved; now compounded |
| Approved use | Visceral fat in HIV lipodystrophy | Historic diagnostic/pediatric GH uses |
| Mechanism | Stimulates pituitary GH release | Stimulates pituitary GH release |
| Sport status | Banned (WADA) | Banned (WADA) |
Which is better, tesamorelin or sermorelin?
The honest answer depends on what "better" means, and the two drugs are not really competing for the same job.
On evidence, tesamorelin wins clearly. It is an actively FDA-approved medicine with randomized trial data behind a specific indication: reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. Its effect there is real, measured and reviewed by a regulator.
On availability and cost, the picture inverts. Tesamorelin is an expensive prescription drug approved for a narrow population. Sermorelin's original brand (Geref) was withdrawn from the US market for commercial reasons rather than safety, and sermorelin is now supplied largely through compounding pharmacies and wellness clinics — which is why it appears far more often in "peptide therapy" marketing.
For the goals people usually have in mind — anti-ageing, body composition, general vitality — neither has controlled evidence of benefit in healthy adults. Both raise growth hormone. Neither has been shown to convert that into meaningful improvements in strength, body composition or wellbeing in people who are not deficient. Choosing between them on that basis is choosing between two unproven options, and the marketing framing of "which is better" obscures that.
Are tesamorelin and sermorelin the same?
No, though they are close relatives and easy to confuse.
Both are GHRH analogs: synthetic versions of growth hormone-releasing hormone, the hypothalamic signal that tells the pituitary to release growth hormone. Both therefore work upstream, amplifying the body's own pulsatile release rather than supplying growth hormone directly.
The differences are structural and practical:
- Length. Sermorelin is GHRH(1-29), the shortest fragment that retains full activity. Tesamorelin is a modified version of the same fragment with a stabilising group attached, which makes it more resistant to breakdown and longer acting.
- Standing. Tesamorelin is currently FDA-approved. Sermorelin's approval lapsed when its brand was discontinued.
- Where you encounter them. Tesamorelin through the pharmacy for a specific diagnosis; sermorelin mostly through compounding and clinics.
A third relative, CJC-1295, extends the same idea further with a much longer duration — the three form a family, not a set of alternatives.
The bottom line
Bottom line: Both are GHRH analogs, but tesamorelin is a currently-approved drug with a specific indication and trial evidence, whereas sermorelin's approval lapsed and it now reaches patients mainly via compounding pharmacies. Neither is an approved general anti-aging or physique therapy, and both are banned in sport.
Frequently asked questions
What's the difference between tesamorelin and sermorelin?
Both are GHRH analogs that boost growth hormone. Tesamorelin is currently FDA-approved (Egrifta) for HIV-related visceral fat; sermorelin was previously approved and is now usually compounded.
Is sermorelin still FDA-approved?
Sermorelin's branded product (Geref) was discontinued; it is now typically supplied through compounding pharmacies rather than as an approved branded drug. Tesamorelin remains approved.
Are they used for anti-aging?
Neither is an approved anti-aging therapy. Tesamorelin's approval is specific to HIV lipodystrophy. Both are prohibited in sport.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. Peer-reviewed study
- Stanley TL, Falutz J, Mamputu JC, et al. Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014. Peer-reviewed study
- Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024. Peer-reviewed study
- Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011. Peer-reviewed study
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011. Peer-reviewed study
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012. Peer-reviewed study
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. Peer-reviewed study
- Kerrigan JR, Martha PM Jr, Blizzard RM, et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. J Clin Endocrinol Metab. 1994. Peer-reviewed study
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. Peer-reviewed study
- Chang Y, Huang R, Zhai Y, et al. A potentially effective drug for patients with recurrent glioma: sermorelin. Ann Transl Med. 2021. Peer-reviewed study